Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases

A. Satta, M. Grandi, C. V. Landoni, G. B. Migliori, A. Spanevello, G. Vocaturo, M. Neri

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A study was undertaken to determine the usefulness of ubidecarenone in pulmonary rehabilitation in exercise training programs in the management of chronic obstructive pulmonary disease (COPD). The subjects were 20 patients with COPD who had been participating in an exercise training program for at least four weeks. The patients were randomly assigned either to receive 50 mg of oral ubidecarenone daily or to enter a control group during the program. Oxygen consumption, expired volume, and heart rate were measured during exercise tests before and after training. Maximum oxygen consumption increased 13% in the ubidecarenone-treated patients and 7% in the controls, and maximum expired volume increased 10% in each group. The increases were significant in the ubidecarenone group but not in the controls. Heart rate increased 2% in both groups. It is concluded that ubidecarenone deserves further evaluation in exercise training programs for patients with COPD.

Original languageEnglish
Pages (from-to)754-757
Number of pages4
JournalClinical Therapeutics
Volume13
Issue number6
Publication statusPublished - 1991

Fingerprint

coenzyme Q10
Chronic Obstructive Pulmonary Disease
Exercise
Education
Oxygen Consumption
Heart Rate
Exercise Therapy
Exercise Test
Lung
Control Groups

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. / Satta, A.; Grandi, M.; Landoni, C. V.; Migliori, G. B.; Spanevello, A.; Vocaturo, G.; Neri, M.

In: Clinical Therapeutics, Vol. 13, No. 6, 1991, p. 754-757.

Research output: Contribution to journalArticle

@article{24094d41b34d480db4ecff40547737b2,
title = "Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases",
abstract = "A study was undertaken to determine the usefulness of ubidecarenone in pulmonary rehabilitation in exercise training programs in the management of chronic obstructive pulmonary disease (COPD). The subjects were 20 patients with COPD who had been participating in an exercise training program for at least four weeks. The patients were randomly assigned either to receive 50 mg of oral ubidecarenone daily or to enter a control group during the program. Oxygen consumption, expired volume, and heart rate were measured during exercise tests before and after training. Maximum oxygen consumption increased 13{\%} in the ubidecarenone-treated patients and 7{\%} in the controls, and maximum expired volume increased 10{\%} in each group. The increases were significant in the ubidecarenone group but not in the controls. Heart rate increased 2{\%} in both groups. It is concluded that ubidecarenone deserves further evaluation in exercise training programs for patients with COPD.",
author = "A. Satta and M. Grandi and Landoni, {C. V.} and Migliori, {G. B.} and A. Spanevello and G. Vocaturo and M. Neri",
year = "1991",
language = "English",
volume = "13",
pages = "754--757",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases

AU - Satta, A.

AU - Grandi, M.

AU - Landoni, C. V.

AU - Migliori, G. B.

AU - Spanevello, A.

AU - Vocaturo, G.

AU - Neri, M.

PY - 1991

Y1 - 1991

N2 - A study was undertaken to determine the usefulness of ubidecarenone in pulmonary rehabilitation in exercise training programs in the management of chronic obstructive pulmonary disease (COPD). The subjects were 20 patients with COPD who had been participating in an exercise training program for at least four weeks. The patients were randomly assigned either to receive 50 mg of oral ubidecarenone daily or to enter a control group during the program. Oxygen consumption, expired volume, and heart rate were measured during exercise tests before and after training. Maximum oxygen consumption increased 13% in the ubidecarenone-treated patients and 7% in the controls, and maximum expired volume increased 10% in each group. The increases were significant in the ubidecarenone group but not in the controls. Heart rate increased 2% in both groups. It is concluded that ubidecarenone deserves further evaluation in exercise training programs for patients with COPD.

AB - A study was undertaken to determine the usefulness of ubidecarenone in pulmonary rehabilitation in exercise training programs in the management of chronic obstructive pulmonary disease (COPD). The subjects were 20 patients with COPD who had been participating in an exercise training program for at least four weeks. The patients were randomly assigned either to receive 50 mg of oral ubidecarenone daily or to enter a control group during the program. Oxygen consumption, expired volume, and heart rate were measured during exercise tests before and after training. Maximum oxygen consumption increased 13% in the ubidecarenone-treated patients and 7% in the controls, and maximum expired volume increased 10% in each group. The increases were significant in the ubidecarenone group but not in the controls. Heart rate increased 2% in both groups. It is concluded that ubidecarenone deserves further evaluation in exercise training programs for patients with COPD.

UR - http://www.scopus.com/inward/record.url?scp=0026355154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026355154&partnerID=8YFLogxK

M3 - Article

C2 - 1790550

AN - SCOPUS:0026355154

VL - 13

SP - 754

EP - 757

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -